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Cardiac troponins and natriuretic peptides are established for risk stratification in light-chain
amyloidosis. Data on cardiac biomarkers in transthyretin amyloidosis (ATTR) are lacking.
Methods and results
Patients (n = 1617) with any of the following cardiac biomarkers, BNP (n = 1079), NT-proBNP
(n = 550), troponin T (n = 274), and troponin I (n = 108), available at baseline in the Transthyr-
etin Amyloidosis Outcomes Survey (THAOS) were analyzed for differences between geno-
types and phenotypes and their association with survival. Median level of BNP was 68.0 pg/
mL (IQR 30.5–194.9), NT-proBNP 337.9 pg/mL (IQR 73.0–2584.0), troponin T 0.03 μg/L
(IQR 0.01–0.05), and troponin I 0.08 μg/L (IQR 0.04–0.13). NT-proBNP and BNP were higher
in wild-type than mutant-type ATTR, troponin T and I did not differ, respectively. Non-Val30-
Met patients had higher BNP, NT-proBNP and troponin T levels than Val30Met patients, but
not troponin I. Late-onset Val30Met was associated with higher levels of troponin I and tropo-
nin T compared with early-onset. 115 patients died during a median follow-up of 1.2 years.
Mortality increased with increasing quartiles (BNP/NT-proBNP Q1 = 1.7%, Q2 = 5.2%, Q3 =
21.7%, Q4 = 71.3%; troponin T/I Q1 = 6.5%, Q2 = 14.5%, Q3 = 33.9%, Q4 = 45.2%). Three-
year overall-survival estimates for BNP/NT-proBNP and troponin T/I quartiles differed signifi-
cantly (p<0.001). Stepwise risk stratification was achieved by combining NT-proBNP/BNP
and troponin T/I. From Cox proportional hazards model, age, modified body mass index,
mutation (Val30Met vs. Non-Val30Met) and BNP/NT-proBNP (Q1–Q3 pooled vs. Q4) were
identified as independent predictors of survival in patients with mutant-type ATTR.
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Conclusions
In this ATTR patient cohort, cardiac biomarkers were abnormal in a substantial percentage
of patients irrespective of genotype. Along with age, mBMI, and mutation (Val30Met vs.
Non-Val30Met), cardiac biomarkers were associated with surrogates of disease severity




Transthyretin (TTR) amyloidosis (ATTR) is the most common form of hereditary systemic
amyloid disease with a broad spectrum of genotypes and heterogeneous phenotypes. TTR is a
tetramer that binds thyroxine and retinol binding protein. Dissociation of the tetramer into
monomers is regarded as the initial step into amyloid formation, and TTR mutations and
advanced age increases the instability of the tetramer and facilitates its dissociation into mono-
mers that, following conformational changes, reassembles into amyloid fibrils [1].
More than 100 amyloidogenic TTR point mutants are described, of which the TTR Val30-
Met preferentially gives rise to a sensorimotor amyloidotic polyneuropathy (TTR-FAP) [2],
whereas other mutations, such as the Val122Ile, predispose to the development of cardiomyop-
athy (TTR-FAC) [3–8]. Age of disease onset and clinical presentation depend on endemic
area, gender, and the underlying genotype. Moreover, wild-type (WT) TTR can assemble into
amyloid fibrils, leading predominantly to an amyloid cardiomyopathy: senile systemic amy-
loidosis. This age- and gender-related amyloidosis is found in a large number of predomi-
nantly male patients, older than 75 years, with heart failure and preserved ejection fraction [9].
Despite the similar histological and morphological presentation of cardiac amyloid, median
survival of patients with ATTR is superior to that of individuals with light-chain amyloidosis
(AL) [10]. At present, clinical variables that may be useful for assessment of disease severity
and prognosis in patients with ATTR are not elucidated in detail [11,12]. In patients with
AL, plasma levels of cardiac troponin T and N-terminal pro-brain natriuretic peptide (NT-
proBNP) provide potent clinical information [9,13–15]. Cardiac troponin T is a highly specific
and sensitive marker of myocardial injury [16,17], while NT-proBNP may be considered a sen-
sitive indicator of cardiac overload. Data on cardiac biomarkers in different types of ATTR are
lacking.
In the Transthyretin Amyloidosis Outcomes Survey (THAOS), data on cardiac biomarkers
troponin T, troponin I, NT-proBNP, and BNP from a large and heterogeneous cohort of
patients with different types of ATTR are recorded. 2535 patients have been entered in the
study as of 06 January 2015, providing a unique opportunity to identify the impact of geno-
types and phenotypes on cardiac biomarkers and their association with survival.
Methods
THAOS is an ongoing international, longitudinal, observational registry that collects data on
the natural history of ATTR (ClinicalTrials.gov: NCT00628745; http://www.clinicaltrials.gov/
ct2/show/NCT00628745), open to all patients with hereditary or WT ATTR and asymptomatic
TTR-variant carriers [18]. Prior to enrolling patients in THAOS, participating sites obtained
Biomarkers in ATTR amyloidosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0173086 April 6, 2017 2 / 17
reporting and quality of life assessment. A
Scientific Board comprising participating
physicians, clinical experts, and a medical
representative of the sponsor gave advice on
scientific and policy decisions and oversaw data
review and analysis. The funder provided statistical
support, and the statistician participated as an
author, but other than this, the funder had no role
in the decision to publish, in the interpretation of
the findings, or in the writing of the manuscript.
Assistance in preparing the manuscript for
submission (editing and formatting of tables and
text) was provided by Shuang Li, PhD, at Engage
Scientific and was funded by Pfizer Inc. The
authors take full responsibility for the content of the
article.
Competing interests: A. V. K. has received
research support from and served on advisory
boards for Pfizer Inc. including the THAOS
scientific advisory board. M. S. M. has received
support from FoldRx Pharmaceuticals, which was
acquired by Pfizer Inc. in October 2010, as a
clinical investigator and for scientific meeting
expenses. His institution has received grant
support from Pfizer Inc. He serves on the THAOS
scientific advisory board. C. R. has received
unrestricted research grants from Pfizer Inc. He
serves on the THAOS scientific advisory board. R.
M. is an employee of Pfizer Inc. and holds stock
options in Pfizer Inc. O. B. S. served as an advisor
for Alnylam Pharmaceuticals, Isis Pharmaceuticals,
and Pfizer Inc. as well as having served as an
advisor and receiving support as a clinical
investigator from FoldRx Pharmaceuticals, which
was acquired by Pfizer Inc. in October 2010. He
currently serves on the THAOS (natural history
disease registry) scientific advisory board. T. D.
has received research support from and served on
advisory boards for Pfizer Inc. including the THAOS
scientific advisory board. This does not alter our
adherence to PLOS ONE policies on sharing data
and materials.
approval from their local Ethical Review Board/Institutional Review Board and satisfied all
national ethical and regulatory requirements. All patients were more than 18 years of age and
provided written informed consent. Confidentiality is maintained according to applicable reg-
ulations and guidelines. Research is in accordance with the Declaration of Helsinki. A Scien-
tific Board comprising participating physicians, clinical experts, and a medical representative
of the sponsor gave advice on scientific and policy decisions and oversaw data review and
analysis.
Data collection
Data obtained during routine clinical practice are entered into THAOS at each visit using a
secure internet-based application. Information entered into THAOS is de-identified.
Of the cardiac biomarkers, measurement of NT-proBNP or BNP is encouraged in all
patients. However, the individual physicians decide the examinations performed on their
patients according to their standard of care. Tests are recommended to be performed using
standardized methods as endorsed by national or international societies. To minimize data
entry errors, units for each parameter are clearly specified and there is a user alert if a value
entered falls outside a pre-specified range.
Data extraction and analysis
Data extraction was performed on January 6, 2015 when 2535 patients were entered into the
THAOS registry. Five patients had polymorphisms and were excluded from the analysis. This
study reports on a subgroup of 1617 patients (63.8% of the overall THAOS population) with
data on cardiac biomarkers available at baseline. Data on BNP were available in 1079 patients
(42.6% of the overall THAOS population) and on NT-proBNP in 550 patients (21.7% of the
overall THAOS population); both BNP and NT-proBNP data were available for eight patients.
Data on cardiac biomarkers were reported from 21 of 36 THAOS sites.
Of the 1617 patients with data on natriuretic peptides, troponin T was available in 274
patients (10.8% of the overall THAOS population) and troponin I in 108 patients (4.3% of
the overall THAOS population); both troponin T and troponin I data were available for two
patients. Demographics and levels of cardiac biomarkers were compared among different
types of ATTR: WT vs. mutant (MT) ATTR, Val30Met vs. non-Val30Met mutations, and
symptomatic Val30Met patients with early vs. late onset of disease, respectively. Since each bio-
marker was obtained for clinical indications at respective sites (n = 21) in different laboratories
with different reference values, each biomarker was divided into four quartiles (Q125%;
25%<Q250%; 50%<Q375%; 75%<Q4100%), respectively. These individual quartiles
were subsequently pooled in a combined quartile of natriuretic peptides or troponin. BNP/
NT-proBNP quartile assignment is based on the quartile values of the available measure. In the
case of patients with both BNP and NT-proBNP available, BNP was used. Troponin T/I quar-
tile assignment is based on the quartile values of the available measure. In the case of patients
with both troponin I and T available, troponin I was used. Cardiac biomarkers were defined
as normal if NT-proBNP <1000 pg/mL, BNP<400 pg/mL, troponin T <0.01 μg/L, and tropo-
nin I<0.01 μg/L. Moreover, optimal cut point for cardiac biomarkers were identified by the
approach of Contal and O’Quigley [19].
Clinical data were compared after dividing patients into mutant and non-mutant type.
Mutant patients were separated according to TTR mutation (Val30Met vs. non-Val30Met).
Finally, patients with Val30Met mutation were divided according to early (<50 years of age)
vs. late (50 years of age) onset of disease.
Biomarkers in ATTR amyloidosis
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Statistical analysis
Continuous data were expressed as either mean and standard deviation (SD) or median and
interquartile range depending on the distribution. Categorical variables were expressed as
absolute numbers and percentages. Comparisons between cohorts and subgroups were carried
out using the one-way analysis of variance (ANOVA) and Kruskal–Wallis test as appropriate;
Chi-square test was used for categorical variables. Bonferroni correction was applied for com-
parisons of demographic and baseline characteristics. Pearson’s correlation coefficients were
calculated to examine the association between BNP/NT-proBNP, Troponin I/T, and clinical
echocardiographic parameters. Overall survival was defined as the time between measurement
of biomarkers and death from any cause irrespective of heart/liver transplantation. Differences
in overall survival by levels of BNP/NT-proBNP and troponin I/T (i.e., Q1–Q3 pooled vs. Q4
as well as optimal cut-off points by the approach of Contal and Quigley [19]) were assessed
respectively, using log-rank analysis with right-censoring. The last available follow-up was
used as a cut-off date for censoring patients who did not experience event. Curves were dis-
played by the Kaplan–Meier product limit method. Cox proportional hazards analysis was
carried out to identify potential risk factors of survival. Statistically significant predictors of
survival from the univariate analysis were then included in a multivariate Cox proportional
hazards model. A stepwise selection method was utilized for the entry and retention of vari-
ables in the model. p<0.05 was considered statistically significant. SAS 9.1.3 (Cary, NC, USA)
was used for all analyses.
Results
The present study cohort of 1617 patients with TTR-related amyloidosis consisted of 1452
patients with MT [728 females, 50.1%; median age 41.5 (range 18.3–86.2) years] and 165
patients with WT [8 females, 4.8%; median age 75.3 (range 48.0–89.6) years]. These patients
did not differ from the cohort of patients in THAOS without data on cardiac biomarkers avail-
able except for age, age at onset of ATTR symptoms, prevalence of cardiac symptoms, mBMI,
Karnofsky index, and renal function (Table 1). In total, 952 of 1452 (65.6%) MT patients and
86 of 165 (52.1%) WT patients presented with neurologic symptoms of ATTR. 355 of 1452
(24.4%) MT patients and 152 of 165 (92.1%) WT patients presented with cardiac symptoms of
ATTR. The median age for onset of symptoms was 38.0 (range 10–82) years in MT and 68.8
(range 33–89) years in WT patients. The most common TTR mutation was Val30Met in 1210
patients (83.3% of MT patients). The median BNP plasma level was 68.0 pg/mL [interquartile
range (IQR) 30.5, 194.9] [n = 1079, 169(16%) with abnormal values], median NT-proBNP
plasma level was 337.9 pg/mL (IQR 73.0, 2584.0) [n = 550, 220(40%) with abnormal values].
Median troponin T plasma level was 0.03 μg/L (IQR 0.01, 0.05) [n = 274, 163 (59%) with
abnormal values], median troponin I plasma level was 0.08 μg/L (IQR 0.0, 1.0) [n = 108, 101
(94%) with abnormal values]. In asymptomatic patients, BNP or NT-proBNP values were
above the upper reference limit in 43 (13.1%) and 18 (16.5%) patients, respectively, whereas
troponin T or I values were above the upper reference limit in 7 (15.6%) and 13 (81.3%)
patients, respectively.
Analysis according to type of ATTR
Demographics according to ATTR type and mutation are shown in Table 1. NT-proBNP and
BNP plasma levels of unadjusted analysis in WT vs. MT patients, Val30Met vs. non-Val30Met
mutations, as well as late onset of Val30Met ATTR vs. early onset of disease were presented in
Fig 1, respectively. Comparison of troponin T and troponin I plasma levels is demonstrated in
Biomarkers in ATTR amyloidosis
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Fig 1. However, number of patients with troponin I was limited in the group of Val30Met
patients (n = 6). Thus, comparison of troponin I between early and late onset was excluded.
Analysis according to level of BNP and NT-proBNP
Detailed demographic data according to the combined quartiles of natriuretic peptides are
shown in Table 2. Age and age at onset of symptoms increased significantly from Q1 to Q4. A
higher prevalence of non-Val30Met patients was observed in Q4 as compared to Q1, Q2, and
Q3, respectively. In contrast, percentage of patients with Val30Met mutation was similar in Q1
and Q2 and decreased in Q3 to Q4. Moreover, patients with higher levels of BNP/NT-proBNP
presented with poorer condition as indicated by decrease of Karnofsky index, modified body
mass index (mBMI), and renal function from Q1 to Q4, respectively. Prevalence of neurological
symptoms and liver transplant was higher in Q3 and Q4 as compared with Q1 and Q2. Optimal
cut-off point was 145 pg/mL for BNP (p< .001) and 325 pg/mL for NT-proBNP (p< .001).
Analysis according to level of troponin I and troponin T
Demographics according to the combined quartiles of troponin are shown in Table 2. Age and
age at onset of symptoms increased significantly from Q1 to Q4. Prevalence of non-Val30Met
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354 (38.8%) 507 (31.4%) 0.0002 152
(92.1%)
355 (24.4%) 215 (17.8%) 140 (57.9%) <0.0001 126 (20.5%) 89 (41.8%) <0.0001
Neurological
symptoms
601 (65.8%) 1038 (64.2%) 0.4086 86 (52.1%) 952 (65.6%) 795 (65.7%) 157 (64.9%) 0.8049 595 (96.7%) 200
(93.9%)
0.0668
mBMI (kg/m2g/L) 996 ± 262 1078 ± 236 <0.0001 1080 ± 191 1077 ± 240 1077 ± 235 1079 ± 270 0.9505 1036 ± 232 1091 ± 269 0.0073
(n = 202) (n = 1419) (n = 116) (n = 1303) (n = 1140) (n = 163) (n = 584) (n = 185)
Karnofsky index
(%)
90 [70, 100] 90 [80, 100] <0.0001 80 [70, 90] 90 [80, 100] 90 [80, 100] 80 [70, 90] <0.0001 90 [80, 90] 80 [70, 90] <0.0001
(n = 677) (n = 1451) (n = 106) (n = 1345) (n = 1160) (n = 185) (n = 592) (n = 190)
eGFR (mL/min/
1.73 m2)
87.4 ± 42.3 104.5 ± 120.4 0.0165 55.7 ± 21.1 110.0 ± 125.5 112.9 ± 72.0 94.4 ± 268.9 0.0444 109.8 ± 38.5 81.7 ± 30.1 <0.0001
(n = 292) (n = 1565) (n = 157) (n = 1408) (n = 1186) (n = 222) (n = 606) (n = 198)
History of liver
transplant
157 (17.2%) 249 (15.4%) 0.2369 0 (0%) 249 (17.1%) 228 (18.8%) 21 (8.7%) 0.0001 201 (32.7%) 22 (10.3%) <0.0001
Data are absolute numbers (percentage), mean ± standard deviation, or median [interquartile range]. Cardiac symptoms are defined as coronary artery
disease, dyspnoea, heart failure, myocardial infarction, rhythm disturbances, and syncope. Neurologic symptoms include balance abnormalities, muscle
weakness, neuropathic pain/paresthesia, numbness, temperature or pain insensitivity, tingling, walking disability.
ATTR, transthyretin- amyloidosis; eGFR, estimated glomerular filtration rate; mBMI, modified body mass index.
aP-values are With vs. Without Biomarker data
bP-values are Val30Met vs. non-Val30Met.
cP-values are early onset vs. late onset.
The bonferroni corrected p-value adjusting for nine comparisons is 0.005556.
https://doi.org/10.1371/journal.pone.0173086.t001
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patients was relatively unchanged from Q1 to Q4. The percentage of patients with Val30Met
mutation decreased from Q1 to Q4. Patients with higher levels of troponin T/I presented with
poorer condition as indicated by decrease of Karnofsky index, mBMI, and renal function from
Q1 to Q4, respectively. Prevalence of liver transplant decreased from Q1 to Q4. Results of cor-
relation of cardiac biomarkers with clinical data are shown in detail in Table 3. Optimal cut-off
point was 0.063 μg/L for troponin I (p< .01) and 0.021 μg/L for troponin T (p< .001).
Survival analysis
During a median follow-up of 1.2 years, 115 patients (7.1%) have died in THAOS due to any
cause. Two patients (1.7%) died in the BNP/NT-proBNP quartile Q1 and 6 (5.2%) in Q2,
respectively. There were 25 (21.7%) and 82 (71.3%) fatal events in the BNP/NT-proBNP quar-
tiles Q3 and Q4, respectively. In the cohort of patients with troponin measurements, there
Fig 1. Unadjusted comparison of cardiac biomarkers in patients with ATTR by genotype, mutation, and age at disease onset. (A)
BNP in patients with wild type (WT) vs. mutant type (MT); (B) NT-proBNP in patients with WT vs. MT; (C) Troponin I in patients with WT vs.
MT; (D) Troponin T in patients with WT vs. MT; (E) BNP in patients with Val30Met vs. non-Val30Met mutations; (F) NT-proBNP in patients
with Val30Met vs. non-Val30Met mutations; (G) Troponin I in patients with Val30Met vs. non-Val30Met mutations; (H) Troponin T in patients
with Val30Met vs. non-Val30Met mutations; (I) BNP in patients with early vs. late onset of ATTR due to Val30Met mutation; (J) NT-proBNP
in patients with early vs. late onset of ATTR due to Val30Met mutation; (K) Troponin I in patients with early vs. late onset of ATTR due to
Val30Met mutation; (L) Troponin T in patients with early vs. late onset of ATTR due to Val30Met mutation.
https://doi.org/10.1371/journal.pone.0173086.g001
Biomarkers in ATTR amyloidosis
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were 4 (6.5%), 9 (14.5%), 21 (33.9%), and 28 (45.2%) deaths in Q1, Q2, Q3, and Q4, respec-
tively. Three-year overall survival estimate for the patients below the optimal cut-point for
BNP/NT-proBNP was 98.1% ± 0.6% and was 70.1% ± 3.1% for patients above the optimal cut-
point, with significant difference between the two survival curves (p<0.001). Three-year over-
all survival estimate for the three BNP/NT-proBNP quartiles Q1 to Q3 combined was 95.8% ±
0.8% and of Q4 was 65.2% ± 3.9%, with significant difference between the two survival curves
(p<0.001). Three-year overall survival estimate for the patients below the optimal cut-point
for troponin T/I was 88.6% ± 5.0% and was 43.6% ± 6.0% for patients above the optimal cut-
point, with significant difference between the two survival curves (p<0.001). Three-year over-
all survival estimates for troponin T/I quartiles Q1 to Q3 combined was 73.7% ± 4.8% and of
Q4 was 32.5% ± 8.0%. There was a significant difference between the two survival curves
(p<0.001). By combination of both biomarkers, stepwise risk stratification was achieved
(Stage A: both natriuretic peptides AND troponins above; Stage B: both natriuretic peptides
AND troponins below; Stage C: either of natriuretic peptides OR troponins is above.
Kaplan-Meier curves were produced for patients grouped by optimal cut-off values for
natriuretic peptides (Fig 2) and the combination of both biomarkers (Fig 3).
Results from the univariate analyses are presented in Table 4. Based on these results, age,
gender, mBMI, duration of disease, estimated glomerular filtration rate (eGFR), and Val30-
Met/non-Val30Met were included in the multivariate Cox proportional hazards model. By
multivariate analysis age [hazard ratio (HR) 1.062, 95% confidence interval (CI) 1.062–1.086],
Table 3. Correlations of biomarkers with clinical and echocardiographic parameters.
n r P-Value
Correlation of log-transformed troponin I with
Age 107 0.222 0.021
Septal thickness 52 0.348 0.011
Left ventricular posterior wall thickness 52 0.434 0.001
Duration of disease 92 −0.258 0.013
Correlation of log-transformed troponin T with
Age 274 0.656 <0.001
Left atrial diameter 190 0.452 <0.001
Septal thickness 202 0.556 <0.001
Left ventricular posterior wall thickness 201 0.606 <0.001
Correlation of log-transformed BNP with
Age 1079 0.585 <0.001
mBMI 987 −0.319 <0.001
Left atrial diameter 148 0.571 <0.001
Septal thickness 175 0.605 <0.001
Left ventricular posterior wall 168 0.563 <0.001
Duration of disease 766 0.308 <0.001
Correlation of log-transformed NT-proBNP with
Age 550 0.698 <0.001
mBMI 438 –0.236 <0.001
Left atrial diameter 267 0.337 <0.001
Septal thickness 307 0.654 <0.001
Left ventricular posterior wall thickness 302 0.649 <0.001
Duration of disease 457 0.186 <0.001
mBMI, modified body mass index; (NT-pro)BNP, (n-terminal pro) brain-type natriuretic peptide.
https://doi.org/10.1371/journal.pone.0173086.t003
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Fig 2. Association of survival and plasma levels of natriuretic peptides in patients with ATTR using unadjusted
log-rank test. Survival stratified by natriuretic peptides (BNP/NT-proBNP) optimal cut-off values (A) in the whole cohort;
(B) in patients with wildtype ATTR; (C) in patients with mutant type ATTR; (D) in patients with Val30Met; (E) in patients
with early onset of Val30Met; (F) in patients with late onset of Val30Met; (G) in patients with non-Val30Met; (H) in patients
with Val122Ile. P-values are for the comparison between the combination of above vs. below the cut-off value.
https://doi.org/10.1371/journal.pone.0173086.g002
Biomarkers in ATTR amyloidosis
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Fig 3. Association of survival and plasma levels of cardiac biomarkers in patients with ATTR using unadjusted
log-rank test. Survival stratified by combination of troponin T/I cut-off values as well as NT-proBNP/BNP quartiles cut-
off values (A) in the whole cohort; (B) in patients with wildtype ATTR; (C) in patients with mutant type ATTR; (D) in
patients with Val30Met; (E) in patients with early onset of Val30Met; (F) in patients with late onset of Val30Met; (G) in
patients with non-Val30Met; (H) in patients with Val122Ile. P-values are for the comparison between the combination of
Biomarkers in ATTR amyloidosis
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mutation (Val30Met vs. non-Val30Met, HR 0.367, 95% CI 0.199–0.676), mBMI (HR 0.998,
95% CI 0.996–0.999), and BNP/NT-proBNP (Q1–Q3 pooled vs. Q4, HR 0.508, 95% CI 0.278–
0.928) were independent predictors of survival. Q4 of troponin did not make it to the final
model due to too few non-missing observations.
Discussion
This study comprised a large cohort of patients with different forms of ATTR with cardiac bio-
markers available in the THAOS registry. Cardiac biomarkers were compared between differ-
ent genotypes and phenotypes. Moreover, the predictive value for survival of ATTR was
analyzed.
Among patients with the same subtype, e.g., ATTR, a wide heterogeneity of phenotypes was
reported. For instance, in some patients with Val30Met, mutation symptoms of ATTR started
at the age of 30 years (early onset disease) whereas others became symptomatic not until the
fifth decade of life (late onset disease). Moreover, phenotype of early onset Val30Met is charac-
terized by peripheral sensor-motoric polyneuropathy and conduction disturbances due to
amyloid infiltration of the conductive system, whereas in other mutations, e.g., Val20Ile,
Leu111Met, and Val122Ile, symptoms of heart failure predominate [20–22]. This heterogene-
ity may be explained by environmental factors and differences in amyloid fibril composition
[23,24], and other factors previously noted by analysis of the large population of ATTR
patients entered into THAOS, including age of onset, mutation, and inheritance pattern.
The present data indicated that higher plasma levels of cardiac biomarkers were observed
in genotypes obviously associated with cardiac involvement, e.g., WT amyloidosis, non-Val30-
Met, and late-onset of Val30Met. Interestingly, increased biomarkers were observed in 45–
90% of the patients with obviously neurologic phenotype, potentially indicating unidentified
patients with values above vs. below the cut-off value. Stage A: both natriuretic peptides AND troponins above; Stage B
both natriuretic peptides AND troponins below; Stage C: either of the natriuretic peptides OR troponins is above.
https://doi.org/10.1371/journal.pone.0173086.g003
Table 4. Potential risk factors of survival by univariate analysis.
Parameters Model 1 (All) Model 2 (TTR Mutation)
Hazard ratio (95%
CI)
P-Value Hazard ratio (95%
CI)
P-Value
Age (per year) 1.08 (1.07,1.10) <0.001 1.10 (1.08,1.12) <0.001
Male (vs. female) 3.48 (2.24,5.39) <0.001 2.75 (1.72,4.40) <0.001
Liver transplant at any time (vs. no liver
transplant)
0.99 (0.61,1.61) 0.97 1.36 (0.82,2.25) 0.24
Liver transplant prior to consent (vs. no liver
transplant)
0.67 (0.32,1.37) 0.27 0.86 (0.42,1.79) 0.69
mBMI [per (kg/m2g/L)] 1.00 (1.00–1.00) <0.001 1.00 (1.00–1.00) <0.001
Duration of disease (per year) 1.04 (1.02,1.06) <0.001 1.04 (1.01,1.07) 0.002
eGFR [per (mL/min/1.73 m2)] 0.98 (0.97–0.98) <0.001 0.98 (0.97–0.98) <0.001
Val30Met (vs. non-Val30Met) 0.13 (0.09,0.21) <0.001
Early Onset (vs. Late onset) ‡ 0.185 (0.10,0.34) <0.001
Val122i (vs Non-Val122i) ‡‡ 2.99 (1.60,5.61) <0.001
CI, confidence interval; mBMI modified body mass index; eGFR estimated glomerular filtration rate.
‡ among symptomatic subjects with Val30met mutation
‡‡ among Non-Val30Met subjects
https://doi.org/10.1371/journal.pone.0173086.t004
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cardiac amyloidosis. Cardiac biomarkers were associated with increase of age and decrease of
clinical condition (i.e., decrease of mBMI, Karnofsky index, and renal function) and, finally,
higher plasma levels of troponin T/I or BNP/NT-proBNP were associated with poorer patient
survival, with BNP/NT-proBNP as independent predictors of survival from the multivariate
analysis.
Cardiac biomarkers in ATTR amyloidosis
Several serological markers of heart muscle damage and heart failure have been established for
diagnosis and risk stratification of different cardiac diseases. For instance, troponin T and I are
sensitive markers for damage of cardiomyocytes. Both have been established as predictors of
outcome in acute coronary syndrome [16,17]. Natriuretic peptides indicate cardiac overload
and are widely used in clinical routine for management of heart failure [25].
Cardiac involvement is common in non-Val30Met TTR gene mutations, late-onset of
Val30Met TTR gene mutation, and invariably present in WT patients. It may develop/progress
in MT patients even after liver transplantation [12]. However, the use of cardiac biomarkers in
patients with ATTR has not been elucidated in detail. In the present analysis, a marked varia-
tion of cardiac biomarkers was observed in diverse types of ATTR, underscoring the heteroge-
neity of the disease.
As expected, cardiac biomarkers were above the upper reference limit in a large number of
patients with cardiac symptoms, with higher levels in variants associated with cardiac pheno-
type, e.g., non-Val30Met, late-onset of Val30Met, and WT. Interestingly, even among patients
with supposed neurologic phenotype, elevation of cardiac biomarkers was observed. This
might indicate cardiac damage due to (incidental) amyloid deposition in accordance with a
previous report showing that natriuretic peptide is increased in ATTR with normal estimated
left ventricle filling pressure [26]. Moreover, in a high percentage of patients without cardiac
symptoms, levels of biomarkers above the upper limit of normal reference populations were
observed (troponin I 81.3%, troponin T 15.6%, BNP 13.1%, NT-proBNP 16.5%). However, it
needs to be taken into account that normal value thresholds of the individual biomarker have
been reported in a healthy reference population. Defining abnormality of biomarker values is a
critical step in its clinical use. Even if the value is within the defined reference limits, this may
not necessarily indicate health in a given individual carrying a TTR gene variant. As inclusion
of echocardiography data into THAOS was not mandatory and data were available for only a
small number of patients, we are unable to draw any robust conclusion regarding severity of
cardiac involvement, especially in these patients. In a recent report on the use of cardiac bio-
markers (troponin T and I and BNP) in late onset Val30Met patients, BNP was demonstrated
to be an early indicator of heart failure [27]. In these patients, abnormal values of BNP were
already present in spite of normal basal strain values by echocardiography. Moreover, a corre-
lation of BNP with several parameters of cardiac dysfunction and hypertrophy was demon-
strated. NT-proBNP was not evaluated in this cohort. A significant correlation between
increase of cardiac biomarkers and surrogate parameters was observed, which appears to be
indicative of the severity of cardiac involvement. Thus, the measurement of cardiac biomark-
ers appears to be justified in all patients with ATTR. In cases of abnormal values, echocardiog-
raphy or cardiac magnetic resonance imaging is recommended.
Troponin levels observed in the present study were considerably lower than those observed
in light-chain amyloidosis. This may potentially indicate minor cardiac damage by ATTR
amyloid, probably due to the absence of toxic effects of light-chains, as suggested in experi-
mental models of light-chain amyloidosis [28]. In a Swedish cohort consisting of 29 patients
who were evaluated for familial amyloid polyneuropathy, neither troponin T nor troponin I
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was a reliable marker for cardiac amyloidosis as detected by echocardiography [27]. In the
present study, correlation of log-transformed values of natriuretic peptides was superior to
correlation of raw troponin levels.
In general, in patients with chronic kidney disease, serum creatinine level affects troponin
T, but has less impact on troponin I [29]. Moreover, impairment of renal function may be
caused by interaction of cardiac and renal function (cardio-renal syndrome). Finally, renal
involvement of ATTR, although rare [30], might explain the worsening of renal function. In
total, 15 mutations of the TTR gene have so far been associated with renal involvement;
among these Val30Met is by far the best characterized variant [31].
Survival analyses
In the present analysis, the role of cardiac biomarkers in predicting outcome in patients with
ATTR is presented for the first time. It was demonstrated that higher values of either natriuretic
peptides (BNP>194.9 pg/mL, NT-proBNP>2584.0 pg/mL) or troponin T (>0.05 μg/L) and I
(>0.58 μg/L) were predictive of survival in unadjusted analysis of patients with ATTR; however,
only BNP/NT-proBNP (Q1–Q3 pooled vs. Q4) was identified as an independent predictor of
survival in multivariate analysis. These results are well in line with previous results of light-
chain amyloidosis. In light-chain amyloidosis, increased levels of troponin and NT-proBNP
have been well established as independent predictors of poor outcome [9,15]. Troponin T eleva-
tion has been shown to correlate with a more aggressive disease and decreased survival [9,14]
whereas NT-proBNP is helpful in assessing response to treatment [15]. Both NT-proBNP and
troponins have been incorporated in a staging system widely used in clinical routine [13].
Limitations
There are several limitations of investigations based on data collected in an observational sur-
vey. As data are collected during routine clinical practice from many centers/countries and at
the discretion of the patient’s physician, there are inevitably variations in the type of clinical
investigations conducted and in the completeness of data. Furthermore, such databases only
capture data in pre-determined fields, which means that they are often slow to capture previ-
ously unsuspected manifestations/events. Databases are also subject to other biases, including
variations in the expertise of participating physicians; a tendency for physicians to include the
most affected individuals in the database or enter cardiac biomarker for patients with cardiac
phenotype but not for those with neurologic phenotype; as well as the potential for certain
genotypes to be over-represented. (% ± SE)
Biomarker measures are not available for all patients in the THAOS registry at baseline as
this is not obligatory in this registry. Thus, this poses a strong risk of selection bias by the
attending physicians, especially as both cohorts (i.e., patients with no information on cardiac
biomarkers and those with biomarker measures) differ in age, prevalence of cardiac symptoms,
mBMI, Karnofsky index, and renal function. At the end, the numbers of patients with tropo-
nin T and I are rather low, and availability of confounding factors, e.g., cardiovascular risk fac-
tors or pharmacotherapy of the patients, is limited. BNP/NT-proBNP was associated with
survival in this cohort of patients with ATTR. Besides prediction of survival, troponins and
natriuretic peptides might be helpful to identify cardiac involvement in patients with obviously
sole neurological phenotype.
Conclusions
In this large and heterogeneous cohort of patients with ATTR, cardiac biomarkers (natriuretic
peptides and troponin) were abnormal in a substantial percentage of patients, irrespective of
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genotype and significantly associated with age and gender; they correlated with other measures
of disease severity (mBMI, left ventricular posterior wall thickness, left atrial diameter) with
BNP/NT-proBNP as an independent predictor of survival. Further studies are needed to evalu-
ate whether increased levels of BNP/NT-proBNP reflect unidentified cardiac involvement as it
is independent of the experience required from any investigator for detecting cardiac amyloid-
osis by echocardiography.
Supporting information
S1 Supporting Information. Source data.
(ZIP)
Acknowledgments
The authors thank Onur Karayal (employee of Pfizer Inc.) for assisting with data compilation.
The Scientific Board would like to thank all investigators for their contributions to the vast
base of evidence being captured in the THAOS registry, which is helping clinicians around the
world to better understand and characterize the natural history of the disease.
In addition to posting clinical trial results on the clinicaltrials.gov registry, Pfizer provides
secure access to anonymized patient-level data to qualified researchers in response to scientifi-
cally valid research proposals. Further detail can be found at: http://www.pfizer.com/research/
clinical_trials/trial_data_and_results/data_requests
List of THAOS investigators
Fabio Adrian Barroso, Buenos Aires, Argentina; Marcelo F Rugiero, Buenos Aires, Argentina;
Johan J. Van Cleemput, Leuven, Belgium; Ivailo Tournev, Sofia, Bulgaria; Marcia Waddington
Cruz, Rio de Janeiro, Brazil; Nowell M. Fine, Calgary, Canada; Arnt Volko Kristen, Heidel-
berg,Germany; Hartmut H.J. Schmidt, Muenster, Germany; Tim Zimmermann, Mainz, Ger-
many; Burkhard Gess, Aachen, Germany; Henning Moelgaard, Aarhus, Denmark; Josep
Maria Campistol Plana, Barcelona, Spain; Juan Buades Reines, Palma de Mallorca, Spain; Jose
Gonzalez Costello, Barcelona, Spain; Pablo Garcia Pavia, Majadahonda, Spain; Jose Luis
Munoz Blanco, Madrid, Spain; Violaine Plante-Bordeneuve, Cre´teil, France; David Adams, Le
Kremlin Bicetre, France; Jocelyn Inamo, Fort de France, France; Claudio Rapezzi, Bologna,
Italy; Giuseppe Vita, Messina, Italy; Giampaolo Merlini, Pavia, Italy; Franco Bergesio, Firenze,
Italy; Yoshiki Sekijima, Nagano, Japan; Yukio Ando, Kumamoto, Japan; Sonoko Misawa,
Chiba, Japan; Ga Yeon Lee, Seoul, Republic of Korea; Jeeyoung Oh, Seoul, Republic of Korea;
Maria Alejandra Gonzalez Duarte Briseno, Mexico City, Mexico; Bouke P.C. Hazenberg, Gro-
ningen, Netherlands; Teresa Coelho, Porto, Portugal; Isabel M. Conceicao, Lisbon, Portugal;
Ole B. Suhr, Umea, Sweden; Mathew Shane Maurer, New York, NY, USA; Sanjiv Jayendra
Shah, Chicago, IL, USA; Dianna Quan, Aurora, CO,USA; Daniel Philip Judge, Baltimore, MD,
USA; Stephen Scott Gottlieb, Baltimore, MD, USA; Nitasha Sarswat, Chicago, IL, USA; Srini-
vas C. Murali, Pittsburgh, PA, USA; Stanley Iyadurai, Columbus, OH, USA; William Gerritt
Cotts, Oak Lawn, IL, USA; Brian M. Drachman, Philadelphia, PA, USA; Angela Dispenzieri,
Rochester, MN, USA; David Eric Steidley, Phoenix, AZ, USA;. Scott L. Hummel, Ann Arbor,
MI, USA; Daniel J. Lenihan, Nashville, TN, USA; Hector Osvaldo Ventura, New Orleans, LA,
USA; Daniel L. Jacoby, New Haven, CT, USA; James E. Hoffman, Miami, FL, USA.
Author Contributions
Conceptualization: AVK RM.
Biomarkers in ATTR amyloidosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0173086 April 6, 2017 15 / 17
Data curation: RM.
Formal analysis: RM.
Funding acquisition: AVK MM CR RM OBS TD.
Investigation: AVK MM CR RM OBS TD.
Methodology: AVK RM.
Project administration: AVK RM.




Writing – original draft: AVK RM.
Writing – review & editing: AVK MM CR RM OBS TD.
References
1. Hammarstro¨m P, Wiseman RL, Powers ET, Kelly JW (2003) Prevention of transthyretin amyloid dis-
ease by changing protein misfolding energetics. Science 299: 713–716. https://doi.org/10.1126/
science.1079589 PMID: 12560553
2. Coelho T, Maurer MS, Suhr OB (2013) THAOS—The Transthyretin Amyloidosis Outcomes Survey: ini-
tial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis.
Curr Med Res Opin 29: 63–76. https://doi.org/10.1185/03007995.2012.754348 PMID: 23193944
3. Ando Y, Nakamura M, Araki S (2005) Transthyretin-related familial amyloidotic polyneuropathy. Arch
Neurol 62: 1057–1062. https://doi.org/10.1001/archneur.62.7.1057 PMID: 16009758
4. Benson MD (2012) Pathogenesis of transthyretin amyloidosis. Amyloid 19 Suppl 1: 14–15.
5. Connors LH, Doros G, Sam F, Badiee A, Seldin DC, Skinner M. (2011) Clinical features and survival in
senile systemic amyloidosis: comparison to familial transthyretin cardiomyopathy. Amyloid 18 Suppl 1:
157–159.
6. Dungu JN, Anderson LJ, Whelan CJ, Hawkins PN (2012) Cardiac transthyretin amyloidosis. Heart 98:
1546–1554. https://doi.org/10.1136/heartjnl-2012-301924 PMID: 22888163
7. Hund E, Linke RP, Willig F, Grau A (2001) Transthyretin-associated neuropathic amyloidosis. Patho-
genesis and treatment. Neurology 56: 431–435. PMID: 11261421
8. Saraiva MJ (2002) Hereditary transthyretin amyloidosis: molecular basis and therapeutical strategies.
Expert Rev Mol Med 4: 1–11.
9. Dispenzieri A, Kyle RA, Gertz MA, Therneau TM, Miller WL, Chandrasekaran K, et al. (2003) Survival in
patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 361: 1787–
1789. https://doi.org/10.1016/S0140-6736(03)13396-X PMID: 12781539
10. Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, et al. (2009) Systemic cardiac amyloid-
oses: disease profiles and clinical courses of the 3 main types. Circulation 120: 1203–1212. https://doi.
org/10.1161/CIRCULATIONAHA.108.843334 PMID: 19752327
11. Kristen AV, Haufe S, Schonland SO, Hegenbart U, Schnabel PA, Ro¨cken C, et al. (2013) Skeletal scin-
tigraphy indicates disease severity of cardiac involvement in patients with senile systemic amyloidosis.
Int J Cardiol 164: 179–184. https://doi.org/10.1016/j.ijcard.2011.06.123 PMID: 21764155
12. Suhr OB, Ericzon BG (2012) Selection of hereditary transthyretin amyloid patients for liver transplanta-
tion: the Swedish experience. Amyloid 19 Suppl 1: 78–80.
13. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. (2004) Serum cardiac tro-
ponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.
J Clin Oncol 22: 3751–3757. https://doi.org/10.1200/JCO.2004.03.029 PMID: 15365071
14. Kristen AV, Giannitsis E, Lehrke S, Hegenbart U, Konstandin M, Lindenmaier D, et al. (2010) Assess-
ment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-
Biomarkers in ATTR amyloidosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0173086 April 6, 2017 16 / 17
sensitivity troponin T assay. Blood 116: 2455–2461. https://doi.org/10.1182/blood-2010-02-267708
PMID: 20581312
15. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, et al. (2003) Serum N-terminal
pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circula-
tion 107: 2440–2445. https://doi.org/10.1161/01.CIR.0000068314.02595.B2 PMID: 12719281
16. Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, et al. (2009) Early diagnosis of
myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 361: 858–867. https://doi.
org/10.1056/NEJMoa0900428 PMID: 19710484
17. Steen H, Giannitsis E, Futterer S, Merten C, Juenger C, Katus HA. (2006) Cardiac troponin T at 96
hours after acute myocardial infarction correlates with infarct size and cardiac function. J Am Coll Car-
diol 48: 2192–2194. https://doi.org/10.1016/j.jacc.2006.06.002 PMID: 17161244
18. Plante´-Bordeneuve V, Suhr OB, Maurer MS, White B, Grogan DR, Coelho T. (2013) The Transthyretin
Amyloidosis Outcomes Survey (THAOS) registry: design and methodology. Curr Med Res Opin 29:
77–84. https://doi.org/10.1185/03007995.2012.754349 PMID: 23193943
19. Contal C, O’Quigley J. (1999) An application of changepoint methods in studying the effect of age on
survival in breast cancer. Comput Stat Data Anal 30:253–270.
20. Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, et al. (2012) Prospective evalua-
tion of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy:
the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J 164: 222–228 e221. https://doi.org/
10.1016/j.ahj.2012.04.015 PMID: 22877808
21. Suhr OB, Svendsen IH, Andersson R, Danielsson A, Holmgren G, Ranløv PJ. (2003) Hereditary trans-
thyretin amyloidosis from a Scandinavian perspective. J Intern Med 254: 225–235. PMID: 12930231
22. Jacobson DR, Pan T, Kyle RA, Buxbaum JN (1997) Transthyretin ILE20, a new variant associated with
late-onset cardiac amyloidosis. Hum Mutat 9: 83–85. https://doi.org/10.1002/(SICI)1098-1004(1997)
9:1<83::AID-HUMU19>3.0.CO;2-L PMID: 8990019
23. Gustafsson S, Ihse E, Henein MY, Westermark P, Lindqvist P, Suhr OB. (2012) Amyloid fibril composi-
tion as a predictor of development of cardiomyopathy after liver transplantation for hereditary transthyr-
etin amyloidosis. Transplantation 93: 1017–1023. https://doi.org/10.1097/TP.0b013e31824b3749
PMID: 22395298
24. Ihse E, Ybo A, Suhr O, Lindqvist P, Backman C, Westermark P. (2008) Amyloid fibril composition is
related to the phenotype of hereditary transthyretin V30M amyloidosis. J Pathol 216: 253–261. https://
doi.org/10.1002/path.2411 PMID: 18729067
25. Daniels LB, Maisel AS (2007) Natriuretic peptides. J Am Coll Cardiol 50: 2357–2368. https://doi.org/10.
1016/j.jacc.2007.09.021 PMID: 18154959
26. Damy T, Deux JF, Moutereau S, Guendouz S, Mohty D, et al. (2013) Role of natriuretic peptide to pre-
dict cardiac abnormalities in patients with hereditary transthyretin amyloidosis. Amyloid 20: 212–220.
https://doi.org/10.3109/13506129.2013.825240 PMID: 23964755
27. Suhr OB, Anan I, Backman C, Karlsson A, Lindqvist P, Mo¨rner S, et al. (2008) Do troponin and B-natri-
uretic peptide detect cardiomyopathy in transthyretin amyloidosis? J Intern Med 263: 294–301. https://
doi.org/10.1111/j.1365-2796.2007.01888.x PMID: 18069997
28. Liao R, Jain M, Teller P, Connors LH, Ngoy S, Skinner M, et al. (2001) Infusion of light chains from
patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation
104: 1594–1597. PMID: 11581134
29. Zand Parsa AF, Abdolahi A, Mahdavimazdeh M (2012) Is cardiac biomarkers and left ventricular func-
tion affected by chronic kidney disease? Indian Heart J 64: 479–483. https://doi.org/10.1016/j.ihj.2012.
08.003 PMID: 23102386
30. Westermark P, Bergstro¨m J, Solomon A, Murphy C, Sletten K (2003) Transthyretin-derived senile sys-
temic amyloidosis: clinicopathologic and structural considerations. Amyloid 10 Suppl 1: 48–54.
31. Lobato L, Rocha A (2012) Transthyretin amyloidosis and the kidney. Clin J Am Soc Nephrol 7: 1337–
1346. https://doi.org/10.2215/CJN.08720811 PMID: 22537653
Biomarkers in ATTR amyloidosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0173086 April 6, 2017 17 / 17
